Sapan Gai, CCO at Sovereign Metals, discusses their superior graphite test results. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSPE.L Regulatory News (SPE)

  • There is currently no data for SPE

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

25 Jan 2021 07:00

RNS Number : 6804M
Sopheon PLC
25 January 2021
 

Embargoed release: 07:00hrs Monday 25 January 2021

 

 

 

SOPHEON PLC

("Sopheon", the "Company" or the "Group")

 

TRADING UPDATE

 

Sopheon, the international provider of software and services for Enterprise Innovation Management solutions, provides the following trading update for the year ended 31 December 2020.

 

As in prior years, the final quarter was the strongest of the year for the Group, and in fact stronger than 2019, despite the resurgence of Covid concerns globally. We are pleased to report ongoing commercial traction and material progress in two strategic areas of focus: migration to a Software as a Service ("SaaS") recurring revenue model - giving both enhanced revenue visibility to future periods and improved quality of earnings - and landing large enterprise class contracts with major companies.

 

Total contract value ("TCV") of signed SaaS business grew 274% year on year, due to rapid adoption by our sales teams of the SaaS model for new customers, as well as converting some existing perpetual customers. Annual Recurring Revenue ("ARR") gross retention for the year remained respectable, at 91.5% (2019: 94.2%) but this represented greater than normal attrition, which is unsurprising given the challenging market conditions for some customers last year. Overall, the TCV of all sales bookings increased by 23% year on year, but the shift of emphasis from perpetual to multi-year SaaS means that most of this revenue will be recognized over time, rather than in the year of sale. New wins included global brands such as DuPont and LG, alongside previously announced Mondelēz and Orion. Six of our new customers had initial deal value at $1m or more, compared to just one in 2019, underlining material traction with enterprise sales even in these difficult times.

 

We expect that revenue for the year ended 31 December 2020 will be approximately $30m, in line with our 2019 performance. ARR is expected to rise to $18m (2019: $15.9m). This, coupled with a substantial order book of services, means that revenue visibility1 for 2021 is already at $22m (2019: $18.9m) giving cause for optimism regarding the year ahead.

 

Adjusted EBITDA is expected to be in the region of $5.6m (2019: $6.4m). Net cash on 31 December 2020 was $21.6m (2019: $19.4m), demonstrating the cash generative nature of the business as well as the robust balance sheet. As noted previously, billing seasonality means that this number should rise in the early part of 2021. In addition, costs reflect initial investments in a native cloud platform to enable new SaaS products, that will take us into new market segments. This was in parallel with further investments in our enterprise Accolade platform. These initiatives will continue in 2021.

 

Financial expectations noted above are preliminary, and subject to year-end financial close and audit review processes. In line with our normal reporting schedule, Sopheon plans to issue its results for the year ended 31 December 2020 on 24 March 2021.

 

Sopheon's Chairman, Barry Mence said: "I'm very proud that Sopheon has been able to match prior year revenue and grow total sales bookings in such a difficult global climate. We've done this while simultaneously embarking on a migration of our business from up-front perpetual license sales to a SaaS subscription model - leading to a solid increase in recurring revenues, and providing greater visibility to future years. We believe we have a substantial opportunity ahead of us, and our strong balance sheet gives us the confidence to maintain ambitious investment plans through the pandemic and beyond."

 

 

For further information contact:

Barry Mence (Chairman)Arif Karimjee (CFO)

Sopheon plc

+ 44 (0) 1276 919 560

Carl Holmes/Giles Rolls (Corporate Finance)Alice Lane / Sunila de Silva (ECM)

finnCap Ltd

+ 44 (0) 20 7220 0500

 

About Sopheon. Sopheon (LSE: SPE) partners with customers to provide complete enterprise innovation management solutions including software, expertise, and best practices, that enable them to achieve exceptional long-term revenue growth and profitability. Sopheon's Accolade solution provides unique, fully-integrated coverage for the entire innovation management and new product development lifecycle, including strategic innovation planning, roadmapping, idea and concept development, process and project management, portfolio management and resource planning. Sopheon's solutions have been implemented by over 200 customers with over 60,000 users in over 50 countries. Sopheon is listed on AIM, operated by the London Stock Exchange. For more information, please visit www.sopheon.com.

1 Revenue visibility is defined on page 7 of Sopheon's 2019 annual report which is available from the investor section of www.sopheon.com.

 

The information communicated in this announcement is inside information

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTDZLFLFFLBBBQ
Date   Source Headline
27th Jan 20117:00 amPRNTrading Statement
9th Dec 20107:00 amPRNAmendment to the Terms of Convertible Loan Stock
16th Nov 20107:00 amPRNContract Win
4th Nov 20107:00 amPRNInterim Management Statement
27th Aug 201010:30 amPRNGrant of Options
26th Aug 20107:00 amPRNHalf-yearly Report
22nd Jul 20107:00 amRNSTrading Update
15th Jun 20105:31 pmPRNResult of AGM
15th Jun 20107:00 amPRNAGM Statement
18th May 20107:00 amRNSAfton Chemical Selects Idea Lab
6th May 20107:00 amPRNInterim Management Statement
25th Mar 20107:00 amPRNFinal Results
22nd Mar 20107:00 amRNSiSUSTAINT Alliance Launched
3rd Feb 20107:00 amRNSSopheon Team wins TARDEC Contract
28th Jan 20107:00 amPRNTrading Update
24th Dec 20097:01 amRNSExtension of GEM Equity Line
2nd Dec 20097:00 amRNSVision Strategist Version 5.0 Launched
3rd Nov 20097:00 amPRNInterim Management Statement
2nd Oct 20093:43 pmPRNISSUE OF CONVERTIBLE LOAN STOCK
27th Aug 20097:00 amPRNHalf-yearly Report
16th Jun 200912:34 pmPRNResult of AGM
16th Jun 20097:00 amPRNAGM Statement
19th May 20097:00 amPRNProduct Launch
7th May 20097:00 amPRNInterim Management Statement
26th Mar 20097:00 amPRNFinal Results
18th Mar 20097:00 amRNSBostik Implements Sopheon's Accolade System
11th Mar 20097:00 amRNSContract Win
11th Feb 20097:00 amRNSEnhanced Version of Accolade? Launched
28th Jan 20097:00 amPRNTrading Update
21st Jan 20097:00 amRNSSopheon Partners with Maxsoft
4th Nov 20087:00 amPRNInterim Management Statement
28th Aug 20087:00 amPRNHalf-yearly Report
27th Jun 20083:47 pmPRNDirector/PDMR Shareholding
25th Jun 20087:00 amPRNGrowth Milestone
10th Jun 20087:00 amPRNAGM Statement
16th May 20087:00 amPRNDirector/PDMR Shareholding
15th May 20087:00 amPRNInterim Management Statement
6th May 200810:00 amPRNNotice of AGM
29th Apr 20087:02 amRNSContract Win
1st Apr 200810:00 amPRNGrant of Options
27th Mar 20087:00 amPRNFinal Results
6th Feb 20087:01 amRNSProduct Development
25th Jan 20087:00 amPRNTrading Update
21st Dec 200710:30 amPRNTrading Update
25th Oct 20077:00 amPRNTrading Update
16th Oct 20072:38 pmBUSBeiersdorf Implements Sopheon System in Support of Product Innovation Strategy
16th Oct 20077:01 amRNSContract Win
10th Oct 20072:45 pmBUSLeading European Center for Clinical Trials Research Selects Sopheon's Accolade(R) System
10th Oct 20077:01 amRNSContract Win
1st Oct 20077:02 amRNSContract Win

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.